Evidence map›Paper›PMID 19808012›Full record

ReviewProstaglandins & other lipid mediators2010

Emerging roles of PGE2 receptors in models of neurological disease.

Katrin Andreasson

Abstract readReview
In one paragraph

Review in Prostaglandins & other lipid mediators, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 212 citations in OpenAlex.

  1. Article
  2. Arachidonic acid metabolism in spinal cord injury.Journal of advanced research · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Spatial mapping of the AA-PGEActa neuropathologica · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Katrin AndreassonDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA. kandreas@stanford.edu
Stanford University · US

Funding

Protective Prostaglandin Receptors in Cerebral IschemiaR01NS045727 · NINDS · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2004 to 2015
$3.7M
Prostanoid signaling and inflammation in aging and Alzheimer's diseaseR01AG030209 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2009 to 2013
$1.6M
MODELS OF ALZHEIMER'S DISEASER01AG015799 · NIA · JOHNS HOPKINS UNIVERSITY · PI ANDREASSON, KATRIN I · 2000 to 2003
$982k
NIA NIH HHS R01 AG015799NIA NIH HHS R01 AG030209NINDS NIH HHS R01 NS045727
6 · The paper itself

Abstract

This review presents an overview of the emerging field of prostaglandin signaling in neurological diseases, focusing on PGE(2) signaling through its four E-prostanoid (EP) receptors. A large number of studies have demonstrated a neurotoxic function of the inducible cyclooxygenase COX-2 in a broad spectrum of neurological disease models in the central nervous system (CNS), from models of cerebral ischemia to models of neurodegeneration and inflammation. Since COX-1 and COX-2 catalyze the first committed step in prostaglandin synthesis, an effort is underway to identify the downstream prostaglandin signaling pathways that mediate the toxic effect of COX-2. Recent epidemiologic studies demonstrate that chronic COX-2 inhibition can produce adverse cerebrovascular and cardiovascular effects, indicating that some prostaglandin signaling pathways are beneficial. Consistent with this concept, recent studies demonstrate that in the CNS, specific prostaglandin receptor signaling pathways mediate toxic effects in brain but a larger number appear to mediate paradoxically protective effects. Further complexity is emerging, as exemplified by the PGE(2) EP2 receptor, where cerebroprotective or toxic effects of a particular prostaglandin signaling pathway can differ depending on the context of cerebral injury, for example, in excitotoxicity/hypoxia paradigms versus inflammatory-mediated secondary neurotoxicity. The divergent effects of prostaglandin receptor signaling will likely depend on distinct patterns and dynamics of receptor expression in neurons, endothelial cells, and glia and the specific ways in which these cell types participate in particular models of neurological injury.

Indexed as

Disease Models, AnimalAnimalsModels, BiologicalNervous System DiseasesReceptors, Prostaglandin EReceptors, Prostaglandin E

Identifiers

PMID19808012
PMCPMC2846228
OpenAlexW1995205013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.